Skip to content

Study · Observational study · n = 179 · 2022

2 results

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.

Tanaka K, Okada Y, Tokutsu A, Tanaka Y

Scientific reports7 Jan 2022Cited by 9 (Europe PMC)

PMID34997102 (opens in a new tab)PMCIDPMC8742102 (opens in a new tab)DOI10.1038/s41598-021-04149-z (opens in a new tab)PepBankPUB-34997102
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Real-world data comparing the effectiveness of various glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus (T2DM) are limited. We investigated the clinical effectiveness of liraglutide and dulaglutide in Japanese T2DM in a real-world setting. This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82). We used stabilized propensity score-based inverse probability of treatment weighting (IPTW) to reduce selection bias and confounding by observed covariates. Changes in glycated hemoglobin (HbA1c) at the end of the 12-month treatment were evaluated. After adjustment by stabilized propensity score-based IPTW, no significant differences were observed in patient characteristics between the liraglutide and dulaglutide groups. HbA1c was significantly lower at 12 months in both groups (liraglutide, 8.9 to 7.4%; dulaglutide, 8.7 to 7.5%). Multivariate linear regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents. High baseline HbA1c, the addition of GLP-1 RA treatment modality, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. The effects of liraglutide and dulaglutide on lowering HbA1c levels at 12 months were comparable in a real-world setting.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Japanese patients with type 2 diabetes, the extent of HbA1c change at 12 months did not differ between liraglutide and dulaglutide after weighting.

    In plain wordsIn Japanese adults with type 2 diabetes, liraglutide and dulaglutide lowered HbA1c by a similar amount over 12 months.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c change at 12 months, liraglutide versus dulaglutide
    Study

    n = 179

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Multivariate linear regression analysis showed no differences in the extent of changes in HbA1c at 12 months between the two agents.
    1 context sentence
    Summary · context
    This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82).
  2. 02HumanObservational studyEfficacy outcome

    In Japanese patients with type 2 diabetes, HbA1c was significantly lower at 12 months of liraglutide treatment (8.9% to 7.4%).

    In plain wordsIn Japanese adults with type 2 diabetes, HbA1c fell from 8.9% to 7.4% after 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 12 months, liraglutide
    Study

    n = 97

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c
    8.9%
    liraglutide, baseline
    HbA1c
    7.4%
    liraglutide, 12 months

    Source sentences

    Summary
    liraglutide, 8.9 to 7.4%
    1 context sentence
    Summary · context
    This retrospective study included 179 patients with T2DM who were treated with GLP-1 RA for at least 12 months (liraglutide, n = 97; dulaglutide, n = 82).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.